News
Heavily pretreated myeloma responds to pembrolizumab combo
Key clinical point: Initial results show promising activity for pembrolizumab in combination with lenalidomide and low-dose dexamethasone in...
Video
ASH: First shot across the bow for CAR T cells in multiple myeloma
Key clinical point: The first clinical trial of a CAR targeting BCMA demonstrated strong antimyeloma activity in patients with at least 3 prior...
News
Academic hospitals offer better AML survival
Key clinical point: Academic hospitals tend to have better short- and long-term mortality for patients with AML than nonacademic hospitals. Major...
News
High NLR predicts poor survival in trauma patients
Key clinical point: A high neutrophil to lymphocyte ratio on day 2 and day 5 of surgical ICU admission may be a useful predictor of poor survival...
News
Anti-PD-1, IMiD combo immunotherapy active in heavily pretreated myeloma
In a phase II trial, a combination of pembrolizumab with pomalidomide and dexamethasone induced responses in 60% of patients with heavily...
News
ASH: Rituximab add-on therapy ‘new standard’ in BCP-ALL
Adding rituximab to standard intensive chemotherapy significantly improved event-free survival in adults with Philadelphia-negative, CD20-positive...
News
ASH: First-line ibrutinib beats standard chemo for CLL/SLL in older patients
First-line ibrutinib significantly extends survival in older patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma,...
Video
VIDEO: Midostaurin hits mark in FLT3-mutated AML
The oral multikinase inhibitor midostaurin improved overall survival by 23% when added to standard chemotherapy and given as maintenance therapy...
News
ASH: Oral drug offers alternative to lifelong transfusions in sickle cell
Key clinical point: Hydroxyurea can substitute for chronic transfusions to prevent primary stroke in children with sickle cell disease and...
News
ASH: Donor CAR-T cells elicit responses in mixture of progressive B-cell cancers
Key clinical point: Allogeneic anti-CD19 CAR T-cell therapy showed promise in a treatment approach for B-cell malignancies persisting after...
News
ASH: Gene therapy reduces transfusion needs in beta-thalassemia major
Lentiviral-based gene therapy can lead to transfusion independence in some patients with beta-thalassemia major.